2nd ANNUAL CONFERENCE OF ICCTI
IMMUNOTHERAPY AND CELL THERAPY CLINICAL TRIALS
November 15 – 16, 2012
Hotel Myslivna, Brno, Czech Republic
Day 1, November 15, 2012 | |
---|---|
8:00 – 8:50 | Registration |
8:50 – 9:00 | Opening of the conference – Jaroslav Michalek |
Section A | Chair: Jaroslav Michalek |
9:00 – 9:30 | Jaroslav Michalek ICCTI activities and mission |
9:30 – 10:00 | Catherine Bollard T cell Therapy for Lymphoma |
10:00 – 10:30 | John Barrett Leukemia-antigen specific T cells to prevent or treat relapse of myeloid malignancies |
10:30 – 11:00 | Coffee break |
Section B | Chair: Catherine Bollard |
11:00 – 11:30 | Virgil Schijns Impact of innate immune system stimulation during multimodular immunotherapy against glioblastoma |
11:30 – 12:00 | Kingston Mills Immunotherapeutics and vaccines approaches to cancer based on manipulating regulatory and effector T cells by targeting dendritic cells |
12:00 – 12:30 | Thomas Felzmann A randomised multi-centre phase II study for the treatment of patients suffering from Glioblastoma Multiforme with a dendritic cell-based cancer vaccine |
12:30 – 14:30 | Lunch break |
14:30 – 15:30 | Round Table Discussion (Section A) J. Michalek, C. Bollard, J. Barrett, V. Schijns, K. Mills, T. Felzmann |
15:30 – 16:30 | Round Table Discussion (Section B) J. Michalek, P. Kudela, D. Powell, A. Stathopoulos, Y. Godfrin, E. Smits, M. Foti |
Day 2, November 16, 2012 | |
8:45 – 9:00 | Registration |
Section A | Chair: Yann Godfrin |
9:00 – 9:30 | Pavol Kudela Bacterial ghosts as tumor antigen delivery system for dendritic cell-based cancer immunotherapy |
9:30 – 10:00 | Daniel J. Powell Jr. Innovative approaches to adoptive T cell therapy |
10:00 – 10:30 | Apostolos Stathopoulos Report of ERC-1671 (Gliovac) vaccine use in recurrent GBM patients |
10:30 – 11:00 | Coffee break |
Section B | Chair: Daniel J. Powell Jr. |
11:00 – 11:30 | Yann Godfrin The red blood cell as a new drug formulation – pre clinical and clinical overview |
11:30 – 12:00 | Evelien Smits Immunotherapeutic clinical cell therapy trials using mRNA-electroporated dendritic cells |
12:00 – 12:30 | Maria Foti Development of cell-based molecular signatures for quality controls of dendritic cells therapies |
12:30 – 14:30 | Lunch break |
14:30 – 15:30 | Round Table Discussion (Section A) J. Michalek, C. Bollard, J. Barrett, V. Schijns, K. Mills, T. Felzmann |
15:30 – 16:30 | Round Table Discussion (Section B) J. Michalek, P. Kudela, D. Powell, A. Stathopoulos, Y. Godfrin, E. Smits, M. Foti |
16:30 – 16:45 | Closing remarks – Jaroslav Michalek |